1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014

Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014" provides data on the Orthomyxoviridae Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Orthomyxoviridae Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Orthomyxoviridae Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Orthomyxoviridae Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Orthomyxoviridae Infections 25
Subjects Recruited Over a Period of Time 33
Clinical Trials by Sponsor Type 34
Prominent Sponsors 35
Top Companies Participating in Orthomyxoviridae Infections Therapeutics Clinical Trials 36
Prominent Drugs 37
Clinical Trial Profiles 38
Clinical Trial Overview of Top Companies 38
GlaxoSmithKline plc 38
Clinical Trial Overview of GlaxoSmithKline plc 38
Novartis AG 51
Clinical Trial Overview of Novartis AG 51
Sanofi 61
Clinical Trial Overview of Sanofi 61
AstraZeneca PLC 68
Clinical Trial Overview of AstraZeneca PLC 68
F. Hoffmann-La Roche Ltd. 73
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 73
CSL Limited 77
Clinical Trial Overview of CSL Limited 77
Pfizer Inc. 80
Clinical Trial Overview of Pfizer Inc. 80
Baxter International Inc. 83
Clinical Trial Overview of Baxter International Inc. 83
Novavax, Inc. 85
Clinical Trial Overview of Novavax, Inc. 85
Johnson and Johnson 87
Clinical Trial Overview of Johnson and Johnson 87
Clinical Trial Overview of Top Institutes / Government 89
The National Institute of Allergy and Infectious Diseases 89
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 89
University of Oxford 96
Clinical Trial Overview of University of Oxford 96
The University of Hong Kong 97
Clinical Trial Overview of The University of Hong Kong 97
Centers for Disease Control and Prevention 98
Clinical Trial Overview of Centers for Disease Control and Prevention 98
National Hospital Organization Mie National Hospital 99
Clinical Trial Overview of National Hospital Organization Mie National Hospital 99
PATH 100
Clinical Trial Overview of PATH 100
University Hospitals of Leicester NHS Trust 101
Clinical Trial Overview of University Hospitals of Leicester NHS Trust 101
University of British Columbia 102
Clinical Trial Overview of University of British Columbia 102
University of the Witwatersrand 103
Clinical Trial Overview of University of the Witwatersrand 103
Institut National de la Sante et de la Recherche Medicale 104
Clinical Trial Overview of Institut National de la Sante et de la Recherche Medicale 104
Five Key Clinical Profiles 105
Appendix 139
Abbreviations 139
Definitions 139
Research Methodology 140
Secondary Research 140
About GlobalData 141
Contact Us 141
Disclaimer 141
Source 141

List of Tables
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Orthomyxoviridae Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Orthomyxoviridae Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Orthomyxoviridae Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Orthomyxoviridae Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Orthomyxoviridae Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Orthomyxoviridae Infections Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Orthomyxoviridae Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Orthomyxoviridae Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 29
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 33
Orthomyxoviridae Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 34
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 35
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 36
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 37
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 38
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 51
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 61
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 68
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 73
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by CSL Limited, 2014* 77
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 80
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014* 83
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novavax, Inc., 2014* 85
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 87
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 89
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014* 96
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Hong Kong, 2014* 97
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 98
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Hospital Organization Mie National Hospital, 2014* 99
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by PATH, 2014* 100
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospitals of Leicester NHS Trust, 2014* 101
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of British Columbia, 2014* 102
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of the Witwatersrand, 2014* 103
Orthomyxoviridae Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut National de la Sante et de la Recherche Medicale, 2014* 104

List of Figures
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Orthomyxoviridae Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Orthomyxoviridae Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Orthomyxoviridae Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Orthomyxoviridae Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Orthomyxoviridae Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Orthomyxoviridae Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Orthomyxoviridae Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Orthomyxoviridae Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Orthomyxoviridae Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 33
Orthomyxoviridae Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 34
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 35
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 36
Orthomyxoviridae Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 37
GlobalData Methodology 140

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.